Abstract
Obesity is the most widespread chronic disease today; it occurs when the process of consumption exceeds energy expenditure processes. Since adequate drug treatment for obesity at the moment isn’t found, research and introduction of new substances that activate β3-AR, is a promising pharmacological objective. One such drug became mirabegron known as a drug for the treatment of OAB. It’s stimulating effect on the brown and beige adipose tissue contribute to enhancing fatty acid oxidation and the release of energy, with a decrease in fat mass. However, because of side effects on the cardiovascular system, and a long course of therapy to a clinically significant result, mirabegron is not currently used as a remedy for obesity, but others β3-adrenergic agonists will be designed in the future and they will smooth disadvantages of mirabegron.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
